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The synthesis and characterization of two novel and isomeric hybrid ferrocenyl/cyrhetrenyl aldimines 45 
[(η5-C5H5)Fe{(η5-C5H4)-CHvN-(η5-C5H4)}Re(CO)3] (1) and [(η5-C5H5)Fe{(η5-C5H4)-NvCH-(η5-46 
C5H4)}Re (CO)3] (2) are reported. Their X-ray crystal structures reveal that both adopt the E form. 47 
However, molecules of 1 and 2 differ in the relative arrangement of the “Fe(η5-C5H5)” and “Re(CO)3” 48 
units (anti in 1 and syn in 2). This affects the type of intermolecular interactions, the assembly of the 49 
molecules and therefore their crystal architecture. Comparative studies of their electrochemical, 50 
spectroscopic and photo-physical properties have allowed us to clarify the effect produced by the 51 
location of the organometallic arrays (ferrocenyl or cyrhetrenyl) on electronic delocalization, the 52 
proclivity of the metals to undergo oxidation and their emissive properties. Theoretical studies based on 53 
Density Functional Theory (DFT) calculations on the two compounds have also been carried out in 54 
order to rationalize the experimental results and to assign the bands detected in their electronic spectra. 55 
The cytotoxic activities of compounds 1 and 2 against human adenocarcinoma cell lines [breast (MCF7 56 
and MDA-MB-231) and colon (HCT-116)] reveal that imine 2 has a greater inhibitory growth effect 57 
than 1 and it is ca. 1.8 times more potent than cisplatin in the triple negative MDA-MB 231 and in the 58 
cisplatin resistant HCT-116 cell lines. A comparative study of their effect on the normal and non-tumour 59 






Heterodimetallic compounds have attracted great interest in recent years. The presence of two proximal 66 
metals with different environments, oxidation numbers and spin states may influence their mutual 67 
cooperation, reactivity, electrochemical behaviour, photo-optical properties and also activities (i.e. 68 
catalytic, biological).1–4 Besides this, the proper selection of two metal ions, their environments and 69 
their connectivity (i.e. by metal–metal bonds, ligands’ scaffold or functional groups) may also produce 70 
multifunctional compounds with outstanding relevance in new materials design (i.e. electrochemical 71 
devices, sensors, molecular switches, etc.), photoelectronic technology, nanoscience, catalysis, biology 72 
and medicine.5 73 
On the other hand, bioorganometallic chemistry has been one of the research areas with a greater, and 74 
also faster, development during the last decade.6,7 The great advances achieved so far as well as the 75 
discovery of relevant applications of organometallic compounds in diagnosis, therapy and imaging are 76 
promoting the interest of a large number of scientists, making this area more attractive day after day. 77 
Among the huge variety of organometallic compounds, metallocenes (especially ferrocene derivatives) 78 
and three-legged half sandwich organometallic derivatives are the most promising candidates in 79 
biotechnology, diagnosis and new drug design. Examples of their use as bioprobes for cellular imaging, 80 
pharmaceutical sensors, molecular recognizers, detectors, and artificial metallo-enzymes have been 81 
described, and the idea of using these organometallic complexes in new drug (or prodrug) discovery is 82 
becoming more and more fascinating and popular.8–11 83 
The success of ferrocenyl-based molecules as antimalarial, antitumoral, anti-VIH, antibacterial, and 84 
antifungal agents and inhibitors8–11 has triggered the interest on novel ferrocene derivatives with 85 
greater efficiencies, lower toxicities and minor side effects than the drugs used nowadays for the 86 
treatment of these diseases. It has also allowed the extension of the strategies used for ferrocenes to the 87 
half-sandwich organometallic compounds. Those with fac-[M(CO)3] cores, such as cyrhetrene [Re(η5-88 
C5H5)(CO)3] and cymantrene [Mn(η5-C5H5)(CO)3] derivatives, are attracting a great deal of interest 89 
in new medicinal chemistry due to their high stability in air and water, lipophilicity, low toxicity, 90 
properties (i.e. photo-physical or electrochemical) or biological activities.11–18 91 
Cyrhetrene chemistry has undergone a fast and spectacular growth in the last five-years.11–18 The 92 
development of new hybrid compounds with the “[Re(η5-C5H4)(CO)3]” unit anchored on the 93 
backbones of molecules of biological relevance is one of the most active and promising areas of research 94 
in new medicinal chemistry. The compounds shown in Fig. 1 are representative examples to illustrate 95 
the relevance of cyrhetrenyl derivatives in bioorganometallic chemistry. The amides and sulphonamides 96 
(A and B in Fig. 1) are capable of pharmaceutical sensors, molecular recognizers, detectors, and 97 
artificial metallo-enzymes have been described, and the idea of using these organometallic complexes in 98 
new drug (or prodrug) discovery is becoming more and more fascinating and popular.8–11 99 
The success of ferrocenyl-based molecules as antimalarial, antitumoral, anti-VIH, antibacterial, and 100 
antifungal agents and inhibitors8–11 has triggered the interest on novel ferrocene derivatives with 101 
greater efficiencies, lower toxicities and minor side effects than the drugs used nowadays for the 102 
treatment of these diseases. It has also allowed the extension of the strategies used for ferrocenes to the 103 
half-sandwich organometallic compounds. Those with fac-[M(CO)3] cores, such as cyrhetrene [Re(η5-104 
C5H5)(CO)3] and cymantrene [Mn(η5-C5H5)(CO)3] derivatives, are attracting a great deal of interest 105 
in new medicinal chemistry due to their high stability in air and water, lipophilicity, low toxicity, 106 
properties (i.e. photo-physical or electrochemical) or biological activities.11–18 Cyrhetrene chemistry 107 
has undergone a fast and spectacular growth in the last five-years.11–18 The development of new hybrid 108 
compounds with the “[Re(η5-C5H4)(CO)3]” unit anchored on the backbones of molecules of biological 109 
relevance is one of the most active and promising areas of research in new medicinal chemistry. The 110 
compounds shown in Fig. 1 are representative examples to illustrate the relevance of cyrhetrenyl 111 
derivatives in bioorganometallic chemistry. The amides and sulphonamides (A and B in Fig. 1) are 112 
capable of  inhibiting carbonic anhydrase enzymes.11d Several families of cyrhetrene conjugates with 113 
tamoxifen, hydroxytamoxifen (Fig. 1, C)12 and chloroquine (Fig. 1, D)13 have been prepared and 114 
evaluated as antitumoral or antiparasitic agents against malaria, leishmaniasis or trypanosomiasis.13,14 115 
Compound D has remarkable activity (IC50 = 0.9 μM) against Trypanosoma brucei and low toxicity to 116 
normal human cells. Kowalski and co-workers have recently reported seven new hybrid 117 
cyrhetrene/nucleobase derivatives, of which the uracil conjugates (Fig. 1, E) resulted to be the most 118 
active.14 119 
Other families of cyrhetrene derivatives containing crown ethers, chalcones and azoles as pendant 120 
arms15 or incorporating functional groups of biological relevance (i.e. thiosemicarbazones, azines, 121 
imines) have also been prepared and evaluated as antiparasitic agents.16,17 Imines (Fig. 1, F) (more 122 
cytotoxic than their ferrocenyl analogues and nifurtimox) are amongst the most potent anti-123 
Trypanosoma cruzi agents reported so far.17 These findings suggested that the assembly of the 124 
cyrhetrenyl unit and the imine group enhances their anti-Chagas activity. Besides this, the furyl 125 
derivative (Fig. 1, F) (with XvO) produces reactive oxygen species that may be relevant in view of their 126 
potential antitumoral activity.17d Despite these findings, and the ongoing interest on (a) 127 
ferrocenylimines as antitumoral drugs themselves or as ligands to achieve transition metal complexes 128 
with enhanced cytotoxic activity (representative examples are shown in Fig. 2)18,19 and (b) cyrhetrenyl 129 
derivatives with relevant photophysical properties and biological activities (or both simultaneously),12–130 
17 mixed ferrocenyl/cyrhetrenyl imines are still unknown. 131 
Herein, we present the two novel aldimines R1-CHvN-R2, with R1 = ferrocenyl and R2 = cyrhetrenyl 132 
(1) or vice versa (2) (Chart 1) as the first examples of small molecules containing both organometallic 133 
fragments connected by the imine functionality. Experimental work and computational studies on 134 
compounds 1 and 2 clarify the effects produced by the interchange of the two organometallic arrays on 135 
their structures, stabilities and properties (electrochemical and photo-physical). Also, their effect on two 136 
breast cancer cell lines (MCF7 and triple negative MDA-MB231), the HCT116 colon cancer cell line, 137 
and the non-tumoral human skin fibroblast BJ cell line has been studied. 138 
139 
RESULTS AND DISCUSSION  140 
 141 
 142 
Synthesis and characterization of the compounds 143 
 144 
In the first attempt to achieve the synthesis of the aldimine (1), we decided to use the procedure 145 
described previously for the ferrocenylimines [(η5-C5H5)Fe{(η5-C5H4)-CHvN-R1}] (R1 = phenyl or 146 
benzyl)20,21 that consisted of the reaction of equimolar amounts of the aldehyde [(η5-C5H5)Fe{(η5-147 
C5H4)-CHO}] and the corresponding amine H2N-R1 in refluxing benzene (or toluene) and using Dean 148 
Stark apparatus to remove the benzene (or toluene)–water azeotrope formed. When the reaction was 149 
carried out using cyrhetrenylamine and toluene as solvents, the IR spectra as well as the results obtained 150 
from thin layer chromatography (TLC) of the solution obtained after long refluxing periods (up to two 151 
days) revealed the coexistence of small amounts of the desired aldimine (1) and 152 
ferrocenecarboxaldehyde as the major product. This problem is similar to that found for related 153 
ferrocenylimines [(η5-C5H5)Fe{(η5-C5H4)-C(R2)vN-R1}] with bulky substituents (i.e. R1 = phenyl 154 
rings and R2 = Ph or Me),21–23 which were finally obtained with the aid of activated alumina or 155 
molecular sieves to fulfil the condensation process. In view of this we decided to explore whether the 156 
presence of molecular sieves could improve the process. In this case (Scheme S1, A†), the progress of 157 
the reaction was monitored by IR and TLC and after 24 h, both revealed the absence of the aldehyde. 158 
The 1H-NMR spectrum of the solid obtained after concentration confirmed the formation of imine 1. 159 
This compound was finally purified by diffusion at −18 °C of a CH2Cl2 solution of the raw material 160 
layered with n-hexane. 161 
The preparation of imine 2, which can be visualized as arising from 1 by a simple interchange of the 162 
ferrocenyl and cyrhetrenyl groups, was much easier than that of imine 1. This was achieved by the 163 
treatment of [(η5-C5H5)Fe{(η5-C5H4)-NH2}] and [Re{(η5-C5H4)-CHO}(CO)3] in a 1 : 1 molar ratio 164 
and in refluxing toluene (Scheme S1, B†) but using milder experimental conditions than for 1: shorter 165 
refluxing periods {12 h (for 2) versus 24 h (for 1)}, in the absence of molecular sieves and without the 166 
aid of Dean Stark apparatus.  167 
The new aldimines were isolated in fairly good yields (80% and 85% for 1 and 2, respectively). They are 168 
air-stable solids at room temperature and exhibit high solubility in CH2Cl2, CHCl3, toluene, acetone 169 
and acetonitrile, but they are practically insoluble in hexane. As we will demonstrate later on (see 170 
below), compound 1 hydrolyses slowly in CDCl3 solution at 298 K. 171 
Compounds 1 and 2 were characterized by mass (HRMS and EI) and infrared spectra, X-ray diffraction 172 
and NMR. Their HRMS spectra showed a peak with the expected isotopic pattern at m/z = 547.9945 (for 173 
1) and 547.9939 (for 2) that agree with the calculated value for their [M + H]+ cations (m/z = 547.9954). 174 
The EI spectra of compounds 1 and 2 showed the peaks of the molecular ions and the fragments formed 175 
by the successive loss of the CO ligands. 176 
The common features observed in the IR spectra of 1 and 2 (Experimental section) are (a) the existence 177 
of the typical intense bands of the cyrhetrenyl units in the range of 2020–1930 cm−1 that are ascribed to 178 
the stretching of the pendant CO groups and (b) the presence of another and less intense band at ca. 179 
1615 cm−1. The position of this band is similar to the values reported for ferrocenyl20,21 and 180 
cyrhetrenyl aldimines17 and is assigned to the stretching of the >CvN– functional group. 181 
It is well known that (a) imines may adopt two different forms (E or Z) in solution as well as in the solid 182 
state23 and (b) the presence of bulky substituents attached to the atoms of the >CvN– group may hinder 183 
the free rotation around the C–R1 and or N–R2 bonds giving rotameric species.24,25 In aldimines 1 and 184 
2, the two substituents (ferrocenyl and cyrhetrenyl) are bulky and therefore, two different arrangements 185 
of the “Fe(η5-C5H5)” and “Re(CO)3” units could be expected for the (E) and (Z) forms of the imine. 186 
This is especially relevant in the solid state, because it affects not only the Fe⋯Re separation but also 187 
the arrangement of the rings, which could introduce significant changes on the assembly of the units in 188 
the crystal and the crystal architecture. 189 
Fig. S1† shows a set of isomers (a–d) for compound 1. In the pair (a, b), the imine has the E form, while 190 
in c and d it adopts the Z form. The two isomers of each pair {(a, c) and (b, d)} differ in the relative 191 
disposition of the two metal ions (Fe and Re) in relation to the main plane (herein after referred to as MP 192 
and defined by the two substituted “C5H4” rings and the connector (>CvN– group)). The two metal ions 193 
may be located on the opposite sides of the MP plane {anti (in a and c)} or in the same side {syn (in b 194 
and d)}. Although this is not shown in Fig. S1,† a similar set of isomeric forms could also  195 
be expected for imine 2. 196 
Good X-ray quality red monocrystals of [(η5-C5H5)Fe{(η5-C5H4)-CHvN-(η5-C5H4)}Re(CO)3] (1) 197 
and [(η5-C5H5)Fe{(η5-C5H4)-NvCH(η5-C5H4)}Re(CO)3] (2) were obtained by slow evaporation at 198 
−18 °C of their CH2Cl2 solutions layered with n-hexane. 199 
 200 
Description of the crystal structures of the new aldimines (1 and 2)  201 
The crystal structures of compounds 1 and 2 (Fig. 3 and 4, respectively) confirmed the presence of the 202 
two organometallic units (ferrocenyl and cyrhetrenyl) connected by the functional >CvN– group. A 203 
selection of bond lengths, bond angles and relevant angles between planes is presented in Table 1. 204 
Bond lengths and angles of the ferrocenyl unit fall in the range expected for related 205 
ferrocenylaldimines;20,21,26 the pentagonal rings are planar, and nearly parallel [tilt angles = 1.3° (in 1) 206 
and 1.1° (in 2) and they deviate by ca. 3.7° and 5.3° (in 1 and 2, respectively) from the ideal eclipsed 207 
conformation. In both cases, (a) Re(I) exhibits the typical three legged piano stool geometry bound to 208 
three CO ligands and the substituted C5H4 ring in a η5 fashion and (b) bond distances and angles of the 209 
cyrhetrenyl unit are similar to those found in monosubstituted [Re(η5-C5H4R)(CO)3] 210 
compounds.17,26,27 211 
The >CvN– bond length in compounds 1 and 2 is identical [C11–N1: 1.276(6) Å]. For 1 this value is 212 
similar to that of [(η5-C5H5)Fe{(η5-C5H4)-CHvN-R1}] (R1 = substituted phenyl rings),25,26 while in 213 
2 this is clearly greater than that found in [Re{(η5-C5H4)-NvCHR4}(CO)3] with R4 = 4-nitrofuryl 214 
[1.266(15) Å].17c 215 
As shown in Fig. 3 and 4, the organometallic arrays are in a trans-disposition [torsion angles: C12–N1–216 
C11–C10: 175.9(4)° (in 1) and C10–N1–C11–C12: 179.72(16)° (in 2)] confirming that both aldimines 217 
adopt the E form in the crystals. However, the relative arrangement of “Re(CO)3” and “Fe(η5-C5H5)” is 218 
markedly different: anti in 1 and syn in 2. On these bases, the crystal structure of compound 1 219 
corresponds to isomer a (Fig. S1†), but that of aldimine 2 matches isomer b (Fig. S1†). As a 220 
consequence of this, the distance Fe⋯Re in 1 (7.114 Å) is bigger than that in 2 (6.122 Å) and both 221 
clearly exceed the sum of their van der Waals radii [Fe: 2.19 Å and Re 2.35 Å].28 Moreover, in 1, the 222 
two C5H4 rings are less coplanar than in 2 (angle between their main planes are 12.6° and 7.7°, 223 
respectively). This is also relevant because it is well-known that deviations from co-planarity between 224 
aromatic rings are commonly associated with a decreese of electronic delocalization.  225 
The different arrangement of the “Fe(η5-C5H5)” and “Re(CO)3” units in compounds 1 and 2 also 226 
affects the assembly of the molecules in the crystals. In compound 1, a molecule sited at (x, y, z) is 227 
connected by C–H⋯π interactions involving (a) the C2–H2 bond and the ring defined by the set of 228 
atoms [C12–C16] (Fig. S2†) of another unit at (–x, y, 12 − z) and (b) the H13 atom and the C5H5 ring 229 
of the ferrocenyl group belonging to a molecule on (−x, −1 + y, 12 − z). Additional C–H⋯O short 230 
contacts between the oxygen atoms of the hanging CO ligands and the hydrogen atoms of three 231 
proximal molecules (Fig. S2†) extend the assembly of the molecules in the crystals. 232 
In contrast with the results obtained for 1, in the crystals molecules of 2 are assembled by two co-233 
operative π stacking interactions (Fig. S3†), involving the substituted ring of the ferrocenyl unit of a 234 
molecule and the C5H4 ring of another and proximal one with a head-to-tail orientation, and vice versa 235 
giving dimers (the distance between the centroids of the two rings being 3.498 Å). Additional 236 
intermolecular C–H⋯O interactions between (a) the O1 atom of one molecule and the C8–H8 bond (of 237 
the ferrocenyl group) of a different unit and (b) the O3 atom the C5–H5 bond of the cyrhetrenyl group of 238 
another molecule fulfil the assembly of the dimers. 239 
 240 
Solution studies 241 
1H and 13C-NMR data for both compounds are presented in the Experimental section. In both cases, the 242 
assignment of the signals detected in their spectra has been achieved with the aid of two-dimensional 243 
[1H–1H] NOESY and [1H–13C] HMBC NMR experiments. In the 1H-NMR spectra of the two 244 
aldimines the resonance of the iminic proton appeared as a singlet at 8.29 ppm (for 1) or 8.18 ppm (for 245 
2). The position of these signals agrees with that reported for ferrocenylimines [(η5-C5H5)Fe{(η5-246 
C5H4)-CHvN-R1}] (with R1 = phenyl group)20,21,25 and for the cyrhetrenyl derivatives [Re{(η5-247 
C5H4)-CHvN-R1}],17 respectively, which adopted the E form in the solid state and also in CDCl3. This 248 
indicated that imines 1 and 2 retained the (E)-form in solution (2D-NMR studies described below 249 
confirmed this finding). At higher fields (4.0 ppm < δ < 6.0 ppm), the 1H-NMR spectra showed a set of 250 
five signals: an intense singlet due to the protons of the C5H5 ring, and four triplets (of identical 251 
intensity) that correspond to the two types [(H2 and H5) and (H3 and H4)] of different protons of in 252 
each C5H4 unit. Additional 2D-NMR experiments ([1H–1H] NOESY and [1H–13C] HMBC) allowed 253 
us to fulfil the assignment of the signals. 254 
The [1H–1H] NOESY spectra of freshly prepared solutions of 1 and 2 in CDCl3 at 298 K showed cross 255 
peaks between the resonances due to the imine proton at around 8.1 ppm and those of the protons on the 256 
ortho sites of the two C5H4 rings [pairs (H2 and H5) and (H2 and H5)]. This confirmed the E form of 257 
the imines 1 and 2 in solution and also the identification of the signals due to the two types of protons of 258 
each ring. 259 
13C{1H} NMR spectra of 1 and 2 in CDCl3 at 298 K exhibited a singlet in the low field region (ca. δ ≈ 260 
193 ppm) that corresponds to CO ligands. The resonance due to the imine carbon appeared at 166.6 ppm 261 
(for 1) and at 148.9 ppm (for 2). The position of these signals is in good agreement with those reported 262 
for closely related aldimines [(η5-C5H5)Fe{(η5-C5H4)-CHvN-R1}] (R1 = phenyl group)20,21,25 and 263 
for the cyrhetrenyl derivative type F shown in Fig. 1.17 The up-field shift of the resonance due to the 264 
imine carbon observed for 2 (ca. 18 ppm) in relation to that of 1 suggests that the interchange of the 265 
ferrocenyl and cyrhetrenyl units produces a significant change in the electronic density of the >CvN– 266 
moiety. In both cases the signals due to the ipso carbon atoms of the C5H4 rings (C1 and C1) exhibited 267 
low intensity, appeared in the range 78 ppm ≤ δ ≤ 130 ppm and their chemical shifts were clearly 268 
affected by the nature of the atom to which they are bound (Nimine or Cimine). At higher fields a set of 269 
five additional signals were also observed, of which the most intense one corresponds to the carbon 270 
nuclei of the C5H5 ring and the remaining ones to the two pairs of carbon atoms [(C2 and C5) and (C3 271 
and C4)] of each C5H4 ring (see characterization data for the two compounds). 272 
Study of the stability of compounds 1 and 2 in solution. The stability of the two aldimines in solution 273 
has also been investigated by comparing the 1H-NMR spectrum of a freshly prepared solution of the 274 
corresponding compound in CDCl3, CD3CN or DMSO-d6 with those registered after different periods 275 
of storage (t ) at 298 K.  276 
The 1H-NMR spectrum of the freshly prepared solution of 1 in CDCl3 at 298 K changed with time (Fig. 277 
S4†) and after 4 h of storage additional signals with tiny intensity were also detected. For t = 18 h the 278 
changes became more evident and in this case the analyses of the resonances observed suggested the 279 
coexistence of the aldimine, ferrocenecarboxaldehyde and the amine in a relative abundance: 1.00 : 0.78 280 
: 0.77. Thus, this indicates that compound 1 hydrolyzes slowly in CDCl3. In contrast with the results 281 
obtained for 1, no significant variations in the 1H-NMR spectrum of 2 were detected after long storage 282 
periods (up to five days) (Fig. S5†), thus indicating that 2 is more stable than 1 in CDCl3 and less prone 283 
to hydrolyze. 284 
In order to check also the stability of the aldimines in the solvent used for the electrochemical studies 285 
(see the following section), a parallel study was carried out using acetonitrile-d3 (Fig. S6†). In this case 286 
no significant changes in their NMR spectra were detected after several hours of storage, indicating that 287 
both compounds are stable in this solvent at 298 K.  288 
As mentioned above compounds holding ferrocenyl arrays and organometallic transition metal 289 
complexes with pianostool geometries and fac-[M(CO)3] cores are gaining importance due to their 290 
potential biological activity and utility. In view of this and since for the biological studies described 291 
below, the first step consisted in the dissolution of the compound in DMSO, followed by subsequent 292 
dilutions with water, the stability of the new products in DMSO-d6 was also investigated by 1H-NMR. 293 
As shown in Fig. S7,† the narrow signals observed in the spectrum of the freshly prepared solution of 1 294 
in DMSO-d6 broaden with time. After 4 h, the spectrum showed new sets of signals of which one was 295 
due to ferrocenecarboxaldehyde, probably formed by hydrolysis of the imine group. In contrast with 296 
these results 1H-NMR studies of compound 2 (Fig. S8†) revealed that it is much more stable and robust 297 
than 1 in DMSO-d6. An additional study was carried out with compound 2 using a DMSO-d6 : D2O (4 : 298 
1) mixture showing that it remained practically unaltered under these experimental conditions (298 K) 299 
for several days. The 1H-NMR spectrum registered after 112 h of storage indicated the presence of 2 as 300 
the major product and small amounts of the degradation product (Fig. S9†). 301 
 302 
Comparative study of their electrochemical, photo-optical and 303 
biological activities 304 
Electrochemical behaviour. The electrochemical properties of new isomeric ferrocenyl/cyrhetrenyl 305 
aldimines 1 and 2 were also investigated. As shown above, NMR studies confirmed that both aldimines 306 
were stable in acetonitrile. The electrochemical studies were carried out by cyclic voltammetry of 307 
freshly prepared solutions (10−4 mol L−1) in acetonitrile with (Bu4N)[PF6] as the supporting 308 
electrolyte. All these experiments were carried out at a scan rate υ = 250 mV s−1. Cyclic 309 
voltammograms (hereinafter referred to as CVs) are shown in Fig. 5 and a summary of electrochemical 310 
data for compounds under study is presented in Table 2. 311 
The CVs of the new aldimines showed in the range −1.20 V < E < 0.50 V (Fig. 5A) an oxidation peak 312 
(I) with a directly associated reduction one in the reverse scan (I′), the intensity ratio (Ipa/Ipc) was close 313 
to 1 and the separation between the oxidation and reduction peaks ΔE = (EIpa − EI′ pc was similar to 314 
that obtained for ferrocene under identical experimental conditions. These findings agree with those 315 
expected for a simple reversible one electron-process.29 It is well-known that the proclivity of ferrocene 316 
derivatives to oxidize is strongly dependent on the nature of the substituents.9,30 In general, the 317 
presence of electron withdrawing groups produces an increase of the Epa value, while donor groups 318 
have the opposite effect. 319 
For compound 1 the position of the wave and the anodic potential are similar to those for 320 
ferrocenylaldimines of general formulae [(η5-C5H5)Fe{(η5-C5H4)-CHvN-R4}] and especially to those 321 
with R4 = CH2-C6H5 {EI pa = 0.20 V30} under identical conditions. This suggests that the effect 322 
produced by the Re(η5-C5H5)(CO)3 unit on the proclivity of Fe(II) to oxidize is similar to that of the 323 
benzyl group. In contrast with these results, for isomer 2, the wave shifts to the more cathodic region, 324 
thus indicating that the “–NvCH(η5-C5H4)Re(CO)3” unit is a stronger electron-donor group than “–325 
CHvN(η5-C5H4)Re(CO)3”. 326 
Besides this, the anodic potential (EI pa) of 2 is quite close to that of ferrocene itself, and therefore more 327 
prone to oxidize than 1. It is well-known that in biological systems the accessible redox potential 328 
window ranges only from around −0.40 to +0.80 V versus the normal hydrogen electrode (NHE).31 329 
Compound 2 has a redox potential quite close to that of ferrocene [E(Fc/Fc+) = 0.5 V versus NHE] and 330 
in the range of the biological systems, while that of the aldimine 1 is higher and closer to the upper limit 331 
of the biological range. This differential behaviour may be important in view of their potential utility in 332 
drug design or for their use as biomarkers. 333 
When the cyclic voltammograms were registered in a wider range of potentials [from −1.00 V to +1.60 334 
V], an additional and poorly resolved oxidation peak (II in Fig. 5B) was observed. The potential of this 335 
peak [EIIpa = 1.29 V (for 1) and 1.42 V (for 2)] falls in the range reported for other cyrhetrene 336 
derivatives and has been assigned to the typical oxidation of Re(I) to Re(II).15a In the reverse scan (Fig. 337 
5B), two (for 1) or three (for 2) additional reduction peaks were detected in the range −0.4 V < E < 0.4 338 
V, of which one (I′) corresponds to the reduction of Fe(III) formed during oxidation.  339 
These studies provide conclusive evidence of the effect produced by the location of the ferrocenyl and 340 
cyrhetrenyl arrays in the aldimines R1-CHvN-R2. The shifts detected in the position of anodic peaks 341 
(EIpa and EII pa) for the two isomers suggest that the interchange of the two organometallic units 342 
produces a significant variation in the electronic distribution of charge. In both cases, the first anodic 343 
peak (I) corresponds to the oxidation of the Fe(II) centre, but for 2 it occurs at lower potentials than for 344 
1, thus suggesting that the energy level of the HOMO of 2 is higher than that of 1. Computational 345 
studies described below confirm this hypothesis. 346 
Absorption and emission spectra. As mentioned in the Introduction section, one of the most attractive 347 
properties of compounds holding fac-[M(CO)3] units arises from their potential luminescence that may 348 
allow their use as luminescent probes or sensors. Since the new aldimines contain this array we also 349 
investigated their photophysical properties. First, the UV-vis spectra of 10−4 mol L−1 solutions of 350 
compounds 1 and 2 in CH2Cl2 at 298 K were registered (Fig. 6 and Table 3). In both cases three (for 1) 351 
and four (for 2) intense absorption bands (with extinction coefficients, ε in the range of 10−3–10−4M−1 352 
cm−1) were observed. The position of the band at lower energies (λ ≈ 475 nm) agrees with that of 353 
related ferrocenyl imines and hydrazones32 and has been attributed to a d–d transition of the Fe(II) 354 
centre. Computational studies (see the following section) confirmed this assignment. In the UV-vis 355 
spectrum of complex 2 (Fig. 6), another absorption maximum at λ = 383 nm was observed, which is 356 
characteristic of cyrhetrene derivatives.11,32,33 For 1 this band is not observed in the spectrum 357 
probably due to the presence of more intense bands at lower wavelengths that may mask it. In both cases 358 
two additional and more intense bands were also detected in the range of 220–320 nm. 359 
 360 
Due to the increasing attractiveness of luminescent Re(I) complexes with “Re(CO)3” arrays,6,8,11,12 361 
we also investigated the emissive properties of the new aldimines in CH2Cl2 at 298 K. Upon excitation 362 
at 477 nm, both complexes showed an emission band at 551 nm (Fig. 7A), which, according to the 363 
literature, 33 originates from a 3MLCT phosphorescence state. 364 
As mentioned above, the UV-vis spectrum of compound 2 showed also an additional absorption band λ 365 
= 383 nm, and after excitation at 385 nm, the emission spectra of 2 (Fig. 7B) showed three bands in the 366 
range 400 nm ≤ λ ≤ 500 nm. When the experiment was carried out under identical conditions, but using 367 
1 instead of 2, the emission spectra showed a similar pattern (Fig. 7B). This suggests that the typical 368 
band of the “Re(CO)3” unit was not observed in the UV-vis spectrum. The spectrum of 1 was probably 369 
masked by the intense absorption at higher energies (λ = 314 nm). Time-dependent DFT calculations 370 
(see below) confirmed this hypothesis. 371 
Computational studies. As mentioned above, multifunctional compounds with potential utility in new 372 
materials and technological development are attracting a great deal of inter-est due to their potential 373 
utility in new materials design and technological devices.5 The new aldimines exhibit interesting 374 
photophysical and electrochemical properties and in addition it is well known that imines are valuable 375 
reagents in organic and organometallic synthesis.34 In view of these and in order to compare the 376 
stability of the isomers of 1 and 2 and to explain the effect produced by the interchange of the two 377 
organometallic arrays in R1-CHvN-R2 on their stability, properties and reactivity of the new 378 
compounds, computational calculations on both imines were carried out. Since (a) the X-ray crystal 379 
structures and the NMR studies described above confirmed that imines 1 and 2 adopted the (E) form in 380 
the solid state and also in solution and, (b) the use of molecular models showed that for isomers (types c 381 
and d in Fig. S1†), with the imine in the syn (Z) form, the proximity of the C5H4 rings would introduce 382 
strong steric hindrance that may reduce their stability, only types a and b isomers of the two aldimines 383 
were used in the computational studies. 384 
All the calculations were carried out using the B3LYP hybrid functional35 and the LANL2DZ36a,b (for 385 
Fe and Re) and 6-31G*36c,d (for the remaining atoms) basis set implemented in Gaussian 03 386 
software.37 Geometries of the E-isomers of compounds 1 and 2 with different arrangements of the 387 
“FeCp” and “Re(CO)3” units (types a and b in Fig. S1†) were optimized without imposing any 388 
restriction. Final atomic coordinates of the optimized geometries are included in the ESI† 389 
(Coordinates.xyz file). Bond lengths and angles of isomers 1a and 2b were consistent with those 390 
obtained from X-ray crystal structures (described above). 391 
A comparison of the calculated values of the total energy (ET) obtained for the pairs (1a and 1b) and (2a 392 
and 2b) (Table S1†) revealed that in vacuum, the ET values of isomers (1b and 2b) with the syn 393 
orientation of the Fe(Cp) and Re(CO)3 moieties were slightly smaller than of their anti analogues (1a 394 
and 2a, respectively) [ET (for 1a) – ET (for 1b) = 1.4 kcal mol−1 and ET (for 2a) – ET (for 2b) = 0.8 395 
kcal mol−1]. In CH2Cl2 the difference between the ET values of the two isomers 2a and 2b decreased to 396 
0.2 kcal mol−1, while for the imine [(η5-C5H5)Fe {(η5-C5H4)-CHvN-(η5-C5H4)}Re(CO)3] the total 397 
energy of the anti isomer 1a was found to be 2.7 kcal mol−1 higher than that of 1b. 398 
In order to get further information about the stability of the four isomers, their free energies were also 399 
calculated (Table S1†). The results obtained in vacuum revealed that for 1 the anti isomer (1a) is 1.58 400 
kcal mol−1 more stable than its syn analogue (1b), while for the aldimine 2, the trend is just the 401 
opposite. Moreover, the free energies increase according to the sequence 1a <2b <2a <1b, in vacuum, 402 
thus indicating a decrease in the stability of the four isomers. When the calculations were carried out 403 
taking into account the effect produced by the solvent (CH2Cl2), the calculated free energies followed 404 
the same trend, showing again that isomers 1a and 2b (which are found in the crystal structures) are 405 
more stable than their corresponding partners (1b and 2a, respectively) and the differences ΔGr, defined 406 
as ΔG (of isomer 1b, 2a or 2b) − ΔG (of 1a, the most stable isomer of the set), in CH2Cl2 were higher 407 
than those in vacuum (Table 4). According to the calculation compound 1a is expected to be more stable 408 
in CH2Cl2 than 2b. However, the NMR studies revealed that 1a hydrolysed slowly in CDCl3 and also in 409 
DMSO-d6. This could be due to the presence of traces of HCl and/or residual water in the deuterated 410 
solvents.  411 
Frontier orbitals [HOMO−1, HOMO, LUMO and LUMO+1] for the most stable isomer of each product 412 
(1a, and 2b) are depicted in Fig. 8. The HOMO−1 of 1a and 2b is similar and located on the ferrocenyl 413 
unit. In both cases the HOMO is centered on >CvN– and the ferrocenyl unit, with a minor contribution 414 
of the cyrhetrenyl moiety. The oxidation of the two aldimines involves this orbital. For 2b, its energy 415 
level is higher than that of the HOMO of 1a (Fig. 8); therefore, the removal of one electron is expected 416 
to require less energy than for 1a. This explains the differences observed in the cyclic voltammograms 417 
shown in Fig. 5A and the shift of the first anodic peak (EIpa) to the more cathodic region (Table 2). 418 
Furthermore, comparative analyses of the charge distribution on the metals and imine functional group 419 
for isomers 1a and 2b (Table S2†) showed some interesting features. The interchange of the ferrocenyl 420 
or cyrhetrenyl arrays in R1-CHvN-R2 of 1a (to give 2b) produces significant variations in the charges of 421 
the ipso carbon atoms (C1 and C1′). In contrast, the Mulliken charges on nitrogen are practically 422 
identical in both cases and the values are similar to those found in other ferrocenyl Schiff bases with rich 423 
and versatile coordination ability to transition metal ions [i.e. Pd(II) and Pt(II)].18,25a This is relevant in 424 
view of their potential use as metalloligands to achieve heterotrimetallic complexes containing Fe(II), 425 
Re(I) and an additional metal ion Mm+ such as Pd(II) and Pt(II) among others. However, it should be 426 
noted that in 2b, the imine nitrogen is not as accessible as in 1a due to steric hindrance. 427 
In order to elucidate the origin of the bands detected in the UV-vis spectra in the range 300–500 nm, we 428 
decided to undertake a study based on time-dependent DFT (TD-DFT) methodology38 to achieve the 429 
assignments of the bands and to confirm the existence of an absorption band at around 380 nm not 430 
observed in the UV-vis spectrum of 1. After the optimization of the geometries in vacuum, the 431 
excitation energies and the oscillator strengths were calculated in CH2Cl2 solution (Table S3†). The 432 
calculated absorption spectra for the two pairs of isomers under study (1a, 1b) and (2a, 2b) are presented 433 
in Fig. S10.† 434 
The computational results obtained revealed that the main absorption bands arise from a combination of 435 
several monoelectronic transitions, of which those with greater contributions are presented in Table S3.† 436 
For instance, the band that appears in the range 460–500 nm mainly involves three (for 1a) or two 437 
monoelectronic transitions between MO mainly centred on Fe(II), while that observed in the 438 
experimental UVvis spectrum of 2b at 383 nm results from the HOMO →LUMO transition, and in both 439 
there is a contribution of the cyrhetrenyl unit. Although for 1a, the existence of an absorption band at 440 
around 380 nm was not as evident as for 2a, it showed emission after excitation at the same wavelength 441 
as for 2b (λexc. = 385 nm). This suggested that 1a might also exhibit electronic transitions at around 380 442 
nm. The computational studies confirmed this hypothesis and the presence of an absorption band at 443 
λcalc. = 387.2 nm that arises from two main monoelectronic transitions: the HOMO → LUMO (as for 444 
2b) and the HOMO−1 → LUMO+3. 445 
The experimental UV-vis spectra (Fig. 6) also exhibited two intense and broad bands at lower 446 
wavelengths (λ < 350 nm), and according to these computational studies, they result from a large 447 
number of monoelectronic transitions that take place in a narrow range of energies (Table S3 and Fig. 448 
S10†), of which one of those with greater weight (81% for 1a and 82% for 2b) is the HOMO−2 → 449 
LUMO. For 1a this transition leads to an absorption band at λcalc. = 312 nm, while for 2b it appears 450 
slightly shifted (ca. 11 nm) to lower energies (λcalc. = 323 nm). 451 
Biological studies. Due to increasing interest on organometallic compounds in new drug design, and 452 
especially in cancer therapy, in vitro studies on the effect produced by aldimines 1 and 2 on two human 453 
breast cancer cell lines [MCF7 and MDA-MB231] and the cisplatin resistant HCT-116 colon cell line 454 
were also carried out. In these studies cisplatin was also used as the positive control under identical 455 
experimental conditions. A summary of the results obtained for the inhibition concentrations (IC50 in 456 
μM) is presented in Table 5 and Fig. 9 and viability plots are shown Fig. S11.† 457 
The comparison of results reveals that (a) compound 1 is clearly less active than 2; and (b) aldimine 2 458 
showed a cytotoxic effect similar to that of cisplatin in MCF7, but it resulted ca. two times more potent 459 
on the triple negative (ER, PR and no HER2 over expression) MDA-MB231 cell line. In view of this, 460 
we also evaluated their activity on the cisplatin resistant HCT-116 adenocarcinoma colon cell line. As 461 
shown in Table 5 and Fig. S12† compound 2 had a greater inhibitory growth effect than the reference 462 
drug, while 1 did not show any relevant activity (IC50 > 30 μM). 463 
A parallel study of the antiproliferative effect of the compounds on the normal and non-tumoral human 464 
skin fibroblast BJ cell lines was also carried out. The results, presented in Table 5 and Fig. S12† show 465 
that the cytotoxicity of the compounds increases according to the sequence 1 < cisplatin ≤ 2. Although 466 
compound 2 has an inhibition growth potency on the BJ cell line quite similar to that of cisplatin, it is 467 
particularly attractive due to (a) its remarkable stability in the solid state and also in solution; (b) its 468 
cytotoxic potency that is comparable to (in MCF7) or even greater (in MDA-MB231 and HCT116) than 469 
that of cisplatin; and (c) the fact that it does not contain Pt(II) and consequently might not produce the 470 
typical and undesirable side effects of the conventional platinumbased drugs used clinically.39 471 
472 
CONCLUSIONS  473 
  474 
Two new and isomeric aldimines R1-CHvN-R2 [with R1 = ferrocenyl and R2 = cyrhetrenyl (1) or vice 475 
versa (2)] have been prepared and characterized in the solid state as well as in solution. The interchange 476 
of the position of the two organometallic arrays in the R1-CHvN-R2 backbones produces significant 477 
changes in their structures, the assembly of the molecules in the crystals, their stability, their 478 
electrochemical and photophysical properties and also their biological activity. In particular, and despite 479 
the formal similarity of 1 and 2 and the fact that both imines adopt the E form in the solid state, in 1 the 480 
“FeCp” and “Re(CO)3” arrays are in an anti disposition, while in 2, they are in syn. This affects the type 481 
of assembly of the molecules and the intermolecular interactions. We have also proved that aldimine 2 is 482 
less prone to hydrolyse and more proclive to undergo the first one electron oxidation process than 1. 483 
The results obtained from the theoretical calculations have allowed us not only to compare (a) the 484 
stability of the two isomers of these products with the imine in the E form and differing in the relative 485 
orientation of the “Fe(Cp)” and Re (CO)3 units in vacuum and in CH2Cl2, (b) the effect produced by 486 
the interchange of the substituents on electronic delocalization and charge distribution and (c) the 487 
different electrochemical behaviour, but also to assign the main monoelectronic transitions and the main 488 
absorptions bands observed in their UV-vis spectra. 489 
The new hybrid imines exhibit luminescence in CH2Cl2 at 298 K. These findings together with the 490 
results obtained from their in vitro studies on their antiproliferative effect on the three human cancer cell 491 
lines [breast (MDA-MB231 and MCF7) and colon (HCT-116)] and non-tumoral BJ cells increase the 492 
value of these products as a novel type of multifunctional compound, due to their electrochemical 493 
behaviour, emissive properties or antitumor activity. Among the two new products presented here, 494 
compound 2, with remarkable stability in DMSO and also in DMSO-d6 : water mixtures, appears to be 495 
an excellent candidate for further work mainly centred on its cytotoxic activity against other cancer cell 496 
lines (i.e., lung, ovarian, etc.), its mechanism of action, and also its potential as an theranostic agent.40 497 
Besides this, both imines have additional interest as building blocks and especially as metallo-ligands to 498 
other transition metal ions Mm+ such as Pt(II), Pd(II), and Ru(II), to achieve heterotrimetallic 499 
compounds with three metal centres [Fe(II), Re(I) and Mm+] and “potentially bioactive units”, which 500 
are attractive not only in view of their potential interest in new drug design and development or 501 





General remarks 507 
 508 
[Re{(η5-C5H4)-CHO}(CO)3] and the amines [Re{(η5-C5H4)-NH2} (CO)3] and [{(η5-C5H5)Fe(η5-509 
C5H4)-NH2}(CO)3] were prepared as described previously.41–43 Ferrocene (98%) and 510 
errocenecarboxaldehyde (98%) were obtained from Aldrich and used as received. The solvents 511 
(CH2Cl2, hexane and toluene) were obtained commercially and were purified using standard 512 
methods.44 All manipulations were conducted under an N2 atmosphere using Schlenk techniques. 513 
High resolution mass spectra (HRMS) were recorded at the Servei de Espectrometría de Masses (Univ. 514 
Barcelona) using a LC/MSD-TOF Agilent Technologies instrument and electron impact (EI) mass 515 
spectra were obtained on a Shimadzu GC-MS spectrometer (70 eV) at the Laboratorio de Servicios 516 
Analíticos (Pontificia Universidad Católica de Valparaíso). Infrared spectra of 1 and 2 were obtained 517 
using a Nicolet 400 FTIR instrument with KBr pellets. UV-visible (UV-vis) spectra of 1.0 × 10−4 M 518 
solutions of the compounds in CH2Cl2 were recorded on a Cary 100 scan Varian UV spectrometer at 519 
298 K. Emission spectra of CH2Cl2 solutions of 1 and 2 were obtained on a Horiba Jobin–Yvon SPEX 520 
Nanolog-TM spectrofluorimeter at 298 K. 521 
Routine 1H and 13C{1H} NMR spectra were recorded at 298 K on a Bruker Fourier 300 or a Mercury 522 
400 MHz instrument. High resolution 1H-NMR spectroscopy and two dimensional NMR experiments 523 
were carried out using Bruker 400 Avance III HD equipment. Except where quoted, the solvent used for 524 
NMR studies was CDCl3 (99.9%) and SiMe4 was the internal reference. The assignment of signals 525 
detected in the 1H and 13C{1H} NMR spectra was achieved with the aid of two dimensional [1H–1H] 526 
nuclear Overhauser effect spectroscopy (NOESY) and [1H–13C] heteronuclear multiple-bond 527 
correlation spectroscopy (HMBC) experiments. NMR data are presented in the characterization section 528 
of each compound. Chemical shifts (δ) are given in ppm and the coupling constants ( J) in Hz, the 529 
assignment of the resonances observed refers to the labelling patterns presented in Scheme S1† and the 530 
abbreviations for the multiplicities of the signals are s (singlet) and t (triplet). 1H-NMR studies of 531 
compounds 1 and 2 in acetonitrile-d3 (Fig. S6†) and DMSO-d6 (Fig. S7 and S8†) at 298 K and of 1 in 532 
DMSO-d6 : D2O (4 : 1) (Fig. S9†) were also undertaken in order to evaluate the stability of the 533 
compounds in the solvents used in the electrochemical studies and in the biological studies. 534 
 535 
 536 
Preparation of the compounds 537 
 538 
Synthesis of compound [(η5-C5H5)Fe{(η5-C5H4)-CHvN-(η5-C5H4)}Re(CO)3] (1). To a solution of 539 
[Re{(η5-C5H4)-NH2}(CO)3 (122.7 mg, 3.5 × 10−4 mol) in 20 mL dry toluene, [(η5-C5H5)Fe{(η5-540 
C5H4CHO)}] (75.0 mg, 3.5 × 10−4 mol) and 4 Å molecular sieves (ca. 2.1 g) were added. The flask 541 
containing the resulting mixture was connected to Dean–Stark apparatus and a condenser and then the 542 
reaction mixture was refluxed for 24 h. After this period, the solvent was removed under vacuum giving 543 
a red solid that was later on crystallized from CH2Cl2/hexane at −18 °C to give orange crystals of 1 544 
(yield: 153.2 mg, 2.8 × 10−4 mol, 80%). Characterization data: Mass spectrum: HRMS (m/z): 547.9945, 545 
calc. for: C19H15FeNO3Re: 547.9954; EIMS (based on 187Re) m/z: 547 [M+], 518 [M+−CO], 491 546 
[M+−2CO], 463 [M+−3CO]. IR selected data (KBr; cm−1): 2010[ν(CO)], 1931 [ν(CO)] and 547 
1613[ν(CvN)]. 1H NMR (400 MHz) δ: 8.29 (s, 1 H, –CHvN–), 5.40 [t, 2H, 3J = 2.3, (H2 and H5)]; 5.23 548 
[t, 2H, 3J = 2.3, (H3 and H4)], 4.71 [t, 2H, 3J = 1.9, (H2 and H5)], 4.52 [t, 2H, 3J = 1.9, (H3 and H4)] 549 
and 4.24 (s, 5H, Cp). 13C NMR (75 MHz) δ: 194.5 (CO); 166.6 (>CHvN–); 129.4 (C1); 81.5 (C2 and 550 
C5); 78.9 (C1); 76.5 (C3 and C4); 72.2 (C2 and C5); 69.7 (Cp); and 69.5 (C3 and C4). 551 
Synthesis of compound [(η5-C5H5)Fe{(η5-C5H4)-NvCH-(η5-C5H4)}Re(CO)3 (2). [Re{(η5-C5H4)-552 
CHO}(CO)3] (75.0 mg, 2.1. × 10−4 mol) was added to a solution of [(η5-C5H5)Fe{(η5-C5H4)-NH2}] 553 
(41.5 mg, 2.1 × 10−4 mol) in 20 mL dry toluene. The mixture was refluxed for 12 h and after this 554 
period, the solvent was pumped off giving a red solid, which was later on crystallized by slow 555 
evaporation at −18 °C of a CH2Cl2 solution layered with n-hexane (yield: 96.2 mg, 1.7 × 10−4 mol, 556 
85%). Characterization data: Mass spectrum: HRMS (m/z): 547.9939, calc. for: C19H15FeNO3Re: 557 
547.9954; EIMS (based on 187Re) m/z: 547 [M+], 518 [M+−CO], 491 [M+−2CO], 464 [M+−3CO]. IR 558 
selected data (KBr; cm−1): 2015[ν(CO)], 1932 [ν(CO)] and 1610[ν(CvN)]. 1H NMR (400 MHz) δ:8.18 559 
(s, 1H, –CHvN–), 5.93 [t, 2H, 3J = 2.2, (H2 and H5)], 5.40 [t, 2H, 3J = 2.2, (H3 and H4)], 4.49 [t, 2H, 3J 560 
= 1.8, (H2 and H5)], 4.25 [t, 2H, 3J = 1.8, (H3 and H4)] and 4.20 (s, 5H, Cp). 13C NMR (75 MHz) δ: 561 
193.2 (CO); 148.9 (>CvN–); 104.1 (C1); 101.1 (C1); 85.3 (C2 and C5), 84.70 (C3 and C4); 69.7 (Cp); 562 





A red prism-like specimen of 1 or a red plate-like crystal of 2 (sizes in Table 6) was selected and 568 
mounted on a D8 Venture system equipped with a multilayer monochromator and a Mo microfocus (λ = 569 
0.71073 Å). The frames were integrated with the Bruker SAINT software package using a narrow-frame 570 
algorithm. The integration of the data using an orthorhombic (for 1) and a triclinic unit cell (for 2) 571 
yielded a total of 21 377 (for 1) and 37 637 (for 2) reflections to a maximum θ = 28.30° (for 1) or 30.57° 572 
(for 2) (0.75 Å and 0.70 Å resolution, respectively). For 1, 4125 were independent (average redundancy 573 
5.182, completeness = 99.7%, Rint = 5.94%, Rsig = 4.85% and 3094 (75.01%) were greater than 2 574 
σ(F2)), while for 2, 5064 reflections were independent (average redundancy 7.432, completeness = 575 
99.8%, Rint = 3.06%, Rsig = 1.91% and 4758 (93.96%) were greater than 2 σ(F2)). The final cell 576 
constants and volumes for 1 and 2 (Table 6) are based upon the refinement of XYZ centroids of 577 
reflections above 20 σ(I). Data were corrected for absorption effects using the multi-scan method 578 
(SADABS). The calculated minimum and maximum transmission coefficients (based on the crystal size) 579 
were 0.5655 and 0.7457 for 1 and 0.5529 and 0.7461 for 2. 580 
The structures were solved and refined using the SHELXTL software package45 using the Pbcn (with Z 581 
= 8, for 1) and the P1ˉ (Z = 2, for 2) space group for the formula unit C19H14FeNO3Re. The final 582 
anisotropic full-matrix least-squares refinement on F2 with 226 variables converged at R1 = 3.36 (for 1) 583 
and 1.50% (for 2) for the observed data, and wR2 = 6.01% (for 1) and 3.17% (for 2) for all data. The 584 
largest peak in the final difference electron density synthesis was 0.888 e Å−3 (in 1) and 0.691 e Å−3 (in 585 
2) and the largest hole was −1.093 e Å−3 (in 1) and −1.031 e Å−3 (in 2) with RMS deviations of 0.196 586 
and 0.118 e Å−3 for 1 and 2, respectively. Further detail concerning the resolution and refinement of the 587 
two crystal structures is presented in Table 6. 588 




Electrochemical studies 593 
 594 
Cyclic voltammetric (CV) studies were carried out at room temperature using a potentiostat (Metrohm 595 
Autolab potentiostat) in a three-electrode cell. Each complex was dissolved in acetonitrile containing 0.1 596 
mol L−1 tetrabutylammoniumhexafluorophosphate (Bu4N)[PF6], as the supporting electrolyte to give 597 
10−3 mol L−1 final concentration. A platinum 2 mm working electrode and a platinum coil counter 598 
electrode were used. The reference electrode contained a silver wire with 10 mM silver nitrate in 599 
(Bu4N)[PF6] electrolyte solution. 600 
The working electrode was polished with 0.3 and 0.05 μm alumina slurries, rinsed with distilled water 601 
(18 MΩ cm) and acetone, and dried prior to use. All electrolyte solutions were thoroughly pre-purged 602 
using purified nitrogen gas before use. The measurements were carried out at a scan rate of 0.25 V s−1. 603 
The ferrocene/ferricinium (Fc/Fc+) couple served as the internal reference and appeared at +89 mV (vs 604 
Ag/Ag+) for each experiment. 605 
 606 
 607 
Computational studies 608 
 609 
DFT calculations were carried out using Gaussian 03 software, 37 with the B3LYP functional.35 The 610 
basis set was chosen as follows: LANL2DZ36a,b for Fe and Re and 6-31G*36c,d (including 611 
polarization functions for non-hydrogen atoms) for C, N, O and H. All molecular structures were 612 
optimized without symmetry constraints and characterized as minima by vibrational analysis. Solvent 613 
effects have been included using the CPCM method.46 614 
Biological studies 615 
 616 
Cell culture. Breast cancer (MCF7 and MDA-MB231) cells (from European Collection of Cell Cultures, 617 
ECACC) and colon adenocarcinoma (HCT-116) cells (from the American Type Culture Collection) 618 
were used in all the experiments. Cells were grown as a monolayer culture in minimum essential 619 
medium (DMEM with L-glutamine, without glucose and without sodium pyruvate) in the presence of 620 
10% heat-inactivated fetal calf serum, 10 mM of D-glucose and 0.1% streptomycin/penicillin under 621 
standard culture conditions. 622 
Cell viability assays. For these studies, the compounds were dissolved in 100% DMSO at 50 mM as 623 
stock solution; then, serial dilutions were prepared in DMSO (1 : 1) (in this way the DMSO 624 
concentration in cell media was always the same); and finally, 1 : 500 dilutions of the serial dilutions of 625 
the compounds in cell media were prepared. The assay was performed as described by Givens et al.47  626 
In brief, MDA-MB231 and MCF7 cells were plated at 5000 cells per well and 10 000 cells per well, 627 
respectively, in 100 Μl media in tissue culture 96 well plates (Cultek). After 24 h, the medium was 628 
replaced by 100 μL per well of serial dilution of drugs. Each point concentration was run in triplicate. 629 
Reagent blanks, containing media plus the colorimetric reagent without cells, were run on each plate. 630 
Blank values were subtracted from test values and were routinely 5–10% of uninhibited control values. 631 
The plates were incubated for 72 h. Hexosaminidase activity was measured according to the following 632 
protocol: the media containing the cells were removed and the cells were washed once with PBS; 60 μL 633 
substrate solution (p-nitrophenol-N-acetyl-β-D-glucosamide 7.5 mM [Sigma N-9376], sodium citrate 634 
0.1 M, pH = 5.0, 0.25% Triton X-100) was added to each well and incubated at 37 °C for 1–2 hours; 635 
after this incubation time, a bright yellow color appeared; then, the plates could be developed by adding 636 
90 μL developer solution (Glycine 50 mM, pH = 10.4; EDTA 5 mM); and absorbance was recorded at 637 
410 nm. 638 
The human skin fibroblast cell line BJ was cultured in DMEM in the presence of 10% FBS, 12.5 mM 639 
DE-glucose, 4 mM glutamine, 5 mN pyruvate and 0.5 streptomycin/penicillin. All the cells were 640 
incubated under standard conditions (humidified air with 5% CO2 at 37 °C). The cells were passaged at 641 
confluence by washing once with cation-free HBSS followed by a 3 minute incubation with trypsin ([0.5 642 
μg mL−1]/EDTA [0.2 μg mL−1]) (Gibco-BRL, 15400054) solution in HBSS at 37 °C, and transferred to 643 
its medium. Prior to seeding at a defined cell concentration, the cells were recovered from the medium 644 
by centrifugation and counted. For proliferation studies, the cells were plated at 5000 cells per well in 645 
100 μL media in tissue culture 96 well plates (Cultek). After 24 h, the media were replaced by 100 μL 646 
per well of serial dilution 1 : 2 of compounds 1 and 2. 647 
For comparison purposes, a parallel study with cisplatin was also carried out under identical conditions. 648 
Reagent blanks, containing media plus colorimetric reagent without cells, were run on each plate. Blank 649 
values were subtracted from test values and were routinely 5–10% of uninhibited control values. The 650 
plates were incubated for 72 h. Hexosaminidase activity was measured according to the following 651 
protocol: the media containing the cells were removed and the cells were washed once with PBS; 60 μL 652 
of substrate solution (p-nitrophenol-N-acetyl-beta-D-glucosamide 7.5 mM [Sigma N-9376], sodium 653 
citrate 0.1 M, pH 5.0, 0.25% Triton X-100) was added to each well and incubated at 37 °C for 1–2 654 
hours; after this incubation time, a bright yellow color appeared; then, the plates could be developed by 655 
adding 90 μL developer solution (Glycine 50 mM, pH 10.4; EDTA 5 mM); and absorbance was 656 
recorded at 410 nm. 657 
658 
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Legends to figures 821 
 822 
Figure. 1 Representative examples of cyrhetrenes containing appended bioactive units with relevant 823 
biological activities. 824 
 825 
Figure.2 Examples of ferrocenylimines (A and B) with cytotoxic activity and their Pt(II) complexes (C–826 
E) with greater inhibitory growth potency than their corresponding parent ligands. IC50 values for D 827 
and E in A549 (lung), MDA-MB231 (breast) or HCT116 (colon) cancer cell lines ranged from 1.5 μM 828 
to 10 μM. 829 
 830 
Chart 1 Chemical formulae of the novel hybrid ferrocenyl/cyrhetrenyl aldimines prepared in this work 831 
and the atom labelling scheme. 832 
 833 
Figure.3 The molecular structure of [(η5-C5H5)Fe{(η5-C5H4)-CHvN-(η5-C5H4)Re(CO)3}] (1). 834 
 835 
Figure.4. The molecular structure of [(η5-C5H5)Fe{(η5-C5H4)-NvCH-(η5-C5H4)Re(CO)3}] (2). 836 
 837 
Figure.5 Cyclic voltammograms of the new aldimines 1 and 2, in the ranges of potentials: −1.20 V ≤ E 838 
≤ 0.50 V (A) and −1.00 V ≤ E ≤ 1.60 V (B), together with the labelling system used for the observed 839 
peaks. 840 
 841 
Figure.6 UV-vis spectra of 10−4 M solutions of aldimines 1 and 2 in CH2Cl2 at 298 K. 842 
 843 
Figure.7 Emission spectra of 10−4 M solutions of the aldimines 1 and 2 in CH2Cl2 at 298 K upon 844 
excitation at λexc. = 477 nm (A) or 383 nm (B). 845 
 846 
Figure.8 Frontier orbitals of isomers 1a (left) and 2b (right) together with their energies and the values 847 
of the HOMO–LUMO gap 848 
 849 
Figure.9 A comparative plot of the IC50 values (μM) of 2 and cisplatin against the three cancer cell 850 
lines used in this study: MCF7 and MDA-MB231 (breast) and HCT-116 (colon) cancer cell lines. 851 
852 





















































Table 1 Selected bond lengths (in Å), bond angles (in deg.), and angles between relevant planes (in 906 
deg.) of aldimines: [(η5-C5H5)Fe{(η5-C5H4)-CHvN-(η5-C5H4)}Re(CO)3] (1) and [(η5-C5H5)Fe{(η5-907 




Table 2 The summary of electrochemical data [anodic (Epa)i, cathodic (Epc)i potentials and the 912 
separation between peaks [ΔE = (Epa)I − (Epc)I’] for the new aldimines R1-CHvN-R2 (in V); intensity 913 
ratio (Ipa/Ipc). Data were obtained at a scan rate υ = 250 mV s−1 and referenced to the 914 




Table 3 Absorption and emission spectroscopic data for aldimines R1-CHvN-R2 (1 and 2) in CH2Cl2 at 919 
298 K. Wavelengths, λi (in nm), logarithms of the extinction coefficients {logε, in parenthesis (ε in M−1 920 





Table 4 Relative free energies (ΔG) of isomers, 1b, 2a and 2b in relation to the value obtained for the 926 




Table 5 Cytotoxic activities of the new aldimines (1 and 2) and cisplatin (IC50 values in μM) against 931 
the MCF7 (breast), triple negative MDA-MB231 (breast) and HCT-116 (colon) cell lines together with 932 
the values obtained in the human skin fibroblast BJ cell line. For comparison purposes, values obtained 933 




Table 6 Crystal data and details of the refinement of the crystal structures of the new aldimines: [(η5-938 
C5H5)Fe{(η5-C5H4)-CHvN-(η5-C5H4)}Re (CO)3] (1) and [(η5-C5H5)Fe{(η5-C5H4)-NvCH-(η5-939 
C5H4)Re(CO)3] (2) 940 
 941 
 942 
 943 
 944 
